Lorecivivint is an intra-articular CLK/DYRK inhibitor recently studied in a phase 2 clinical trial for the treatment of knee osteoarthritis (NCT03727022). In this touchIMMUNOLOGY interview, we caught up with Dr. Nancy Lane (University of California Davis, Sacramento, CA, USA) to discuss the aims, design, eligibility criteria and efficacy and safety findings of the study.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘A Phase 2, 104-Week Study of Repeat Lorecivivint Injections Evaluating Safety, Efficacy, and Bone Health Utilizing Quantitative Computed Tomography (qCT) in Knee Osteoarthritis (OA-06).’ (Abstract number: 1894) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What are the unmet needs in the treatment of knee osteoarthritis? (0:36)
- What is lorecivivint and what is the rationale for its use in this indication? (1:03)
- What were the aims, design and eligibility criteria of the study? (2:46)
- What were the efficacy and safety findings of the study? (3:39)
- What were the limitations of the study and what further studies are planned? (4:32)
Disclosures: Nancy Lane discloses consulting for Biosplice, receiving grant/research support from NIA, serving on advisory boards for Xalud and Genescense, and participating in speaker’s bureaus with Amgen.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
